Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE). // The Breast. – URL: https://www.sciencedirect.com/science/article/pii/S0960977626002663?dgcid=rss_sd_all
Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE). The Breast. https://www.sciencedirect.com/science/article/pii/S0960977626002663?dgcid=rss_sd_all
“Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE).” The Breast.
@article{article67547,
title = {Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE)},
journal = {The Breast},
url = {https://www.sciencedirect.com/science/article/pii/S0960977626002663?dgcid=rss_sd_all}
}